271 related articles for article (PubMed ID: 8712798)
1. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Rosenberg SA
Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
[TBL] [Abstract][Full Text] [Related]
2. The development of new cancer therapies based on the molecular identification of cancer regression antigens.
Rosenberg SA
Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458
[TBL] [Abstract][Full Text] [Related]
3. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Robbins PF; el-Gamil M; Li YF; Topalian SL; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg SA
J Immunol; 1995 Jun; 154(11):5944-50. PubMed ID: 7751637
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
5. [Tumor rejection antigen and cancer immunotherapy].
Matsutake T; Nakayama E
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
[TBL] [Abstract][Full Text] [Related]
6. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
8. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
Yannelli JR; Wroblewski JM
Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
10. [Application of gene therapy in tumor adoptive immunotherapy].
Wang C; Zhao Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
[TBL] [Abstract][Full Text] [Related]
12. [Human tumor-rejection antigens and peptides from genes to clinical research].
Itoh K; Yamana H; Shichijo S; Yamada A
Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
[TBL] [Abstract][Full Text] [Related]
13. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
Rosenberg SA
J Natl Cancer Inst; 1996 Nov; 88(22):1635-44. PubMed ID: 8931607
[TBL] [Abstract][Full Text] [Related]
14. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
[TBL] [Abstract][Full Text] [Related]
15. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
16. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
17. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
Li B; Ding J; Larson A; Song S
In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
20. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]